Otsuka reported long-term Phase 3 data for Voyxact (now branded by the company for kidney disease indication), aiming to convert an accelerated approval into full approval. The company said the trial showed stabilization of kidney function when compared with placebo across the extended dataset. The update is intended to strengthen the evidence package for regulators by providing longer follow-up in IgA nephropathy, where durable clinical outcomes and renal function trajectory are central to conversion from accelerated pathways. If the data hold up in the final regulatory review, Otsuka’s move could tighten competition in chronic kidney disease categories that depend on sustained renal benefits rather than short-term surrogate endpoints.